Abstract: A pharmaceutical composition is produced which is useful for treating allergic conditions in humans which comprises an anti-allergenic amount of a compound of the formula: ##SPC1##Or a pharmaceutically acceptable salt or ester thereof, wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are the same or different and each is hydrogen, alkyl, alkoxy, aryl, aralkyl or halogen or any two of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 taken together, with the carbon atoms to which they are attached, form a phenyl, cyclohexyl or cyclohexenyl ring, in combination with a pharmaceutically acceptable carrier.

Abstract: Compounds having the formula: ##SPC1##Wherein R.sub.3 is hydrogen or a lower alkyl group, R.sub.1 is chloro, bromo, or fluoro, and R.sub.2 is an alkoxy group of 1 to 6 carbon atoms or an aryloxy group which may be substituted with at least one alkyl group or halogen group. These compounds are particularly suitable for the preparation of N-cyclopropyl-pyridyl carboxyl amide derivatives that are useful in the treatment of diseases of the nervous systems in humans and in animals.

Abstract: 2-Aryl substituted isoxazolo[2,3-a]pyridinyl halides having the formula I: ##SPC1##wherein R.sub.1, R.sub.2 and R.sub.3 are each hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy or lower alkanoyl; R.sub.4 is hydrogen or lower alkyl; X is a bromide, chloride or iodide salt; and processes for the preparation thereof, are described. The compounds of the invention are useful as anti-inflammatory agents and for the treatment of hyperacidity.

Abstract: Compounds having the formula ##SPC1##Wherein A is a straight or branched chain alkylene group; R.sub.1 is hydrogen, halogen, alkyl, alkoxy, alkylthio, nitro, amino, or cyano; and R.sub.2 is hydrogen, halogen, alkyl, alkoxy, trifluoromethyl, nitro, amino, or cyano; and n is 1 or 2, with the proviso that when n is 2, R.sub.1 is alkyl, alkoxy, or halogen; are useful central nervous system depressants.

Abstract: 6-(.alpha.-3-Acyl-ureidoacetamido)-penicillanic acids and pharmaceutically acceptable non-toxic salts thereof in which the hydrogen atom of the nitrogen atom present in the 3-position is substituted, are effective against Gram-positive and Gram-negative infections, particularly Klebsiella aerobacter infections.

Abstract: Drugs which are suitable for such therapy in treatment of narcotic drug addiction by oral use, e.g., methadone, are formulated to prevent injection abuse through concentration of the active component in aqueous solution by incorporating in a solid dosage or tablet form of such drug an ingestible solid having thickening properties which causes rapid increase in viscosity upon concentration of an aqueous solution thereof.

Abstract: A process for interrupting pregnancy is disclosed which comprises administration to a mammal an interceptive agent selected from a group of sulfonamidoaminophenones. Illustrative of sulfonamidoaminophenone interceptive agents useful in the process of the present invention for interrupting pregnancy are 4'-(N,N-diethylalanyl)-methanesulfonanilide and 4'-[N-.alpha.,.alpha. -dimethylphenethyl)alanyl]methanesulfonanilide.

Abstract: 3-tert.Butyl-5-nitro-N-pyrid-2'-yl salicylamides which have antiparasitic activity, compositions thereof and methods of controlling parasites in animals infected therewith.

Abstract: Pharmaceutical preparations and methods of using the same to treat a host having a condition requiring vasoconstrictive therapy. The preparations comprise a pharmaceutically acceptable carrier and a guanidine compound, or non-toxic acid addition salt thereof, having the structural notation: ##SPC1##Wherein: R.sub.1 is hydrogen or alkyl having 1-4 carbon atoms; R.sub.2 is hydrogen, hydroxy, chloro, fluoro or bromo; and R.sub.3 is hydrogen or the same as R.sub.2 when R.sub.2 is chloro, bromo or fluoro.

Abstract: 3-Carboxyisocoumarins, 2-thiaisocoumarins and related isocarbostyrils are useful anti-allergic agents. Several of these compounds are novel, and a process for their preparation is provided.

Abstract: N-Cyano-N'-heterocyclic-alkylguanidinos which are inhibitors of histamine activity.

Abstract: Pharmaceutical compositions containing as an active ingredient a compound of the formula ##SPC1##WhereinR is hydrogen, methyl or acetyl,R' is hydrogen or methyl, andX is oxygen or sulfur,Or a non-toxic, pharmacologically acceptable acid addition salt thereof; and a method of using the same as opiate antagonists, analgesics and antitussives.

Abstract: Novel analgesic, anti-pyretic, anti-inflammatory compositions containing as the active ingredient the compound, 5-methyl-1-phenyl-2-(1H)-pyridone are described. Such compositions have also been found to cause significant lowering of serum uric acid and glucose levels and to be effective in the treatment of a number of upper respiratory ailments in humans and other mammals. Skin conditions such as dermatitis and poison ivy are also alleviated by this agent. The compositions containing 5-methyl-1-phenyl-2-(1H)-pyridone caused no irritation on oral administration or when applied to specific target tissues showed no significant irritation or other sequelae.

Abstract: Pharmaceutical compositions for the treatment of allergies are produced using coumarin derivatives as the active agent. Certain of these compounds and their salts are novel.

Abstract: A compound .alpha.-[2-(2-Pyridyl)ethylamino]phenylacetic acid dihydrochloride Hemihydrate possesses pharmacological activity as an antihypertensive agent.

Abstract: Basic esters and acid addition salts thereof of substituted o-anilino-phenylacetic acids with pyridinols or pyridine-alkanols have anti-inflammatory and analgesic activity; they are active ingredients of pharmaceutical compositions and can be used for the relief and removal of pain as well as for the treatment of rheumatic, arthritic and other inflammatory complaints; an illustrative example is [o-(2,6-Dichloro-anilino)-phenyl]-acetic acid (2-pyridyl)-methyl ester.

Abstract: A process for the therapeutic treatment of allergy by the systemic administration of a compound of the formula: ##SPC1##Wherein ##SPC2##Is cyclohexane or ##SPC3##And X and Y can be the same or different and are hydrogen, fluoro, chloro, bromo, alkyl of from 1 to 8 carbon atoms, inclusive, or alkoxy of from 1 to 8 carbon atoms, inclusive, and the pharmacologically acceptable salts thereof in association with a pharmaceutical carrier.

Abstract: 2-Amino-1,4-dihydropyridines bearing a carbonyl function in the 5-position and being optionally substituted by lower alkyl or phenyl in the 6-position, and the corresponding 2-amino-1,4,5,6,7,8-hexahydro-5-oxoquinolines, which derivatives are further substituted by a carbonyl group in the 3-position and optionally substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group are antihypertensive agents and coronary vessel dilators. The compounds, of which 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and an amidine.CROSS REFERENCEThis is a division of Ser. No. 438,603 filed Feb. 1, 1974, now U.S. Pat. No. 3,929,798, which in turn is a division of Ser. No. 336,639 filed Feb. 28, 1973, now U.S. Pat. No. 3,867,393.

Abstract: 2-Amino-1,4-dihydropyridines bearing a carbonyl function in the 5-position and being optionally substituted by lower alkyl or phenyl in the 6-position, and the corresponding 2-amino-1,4,5,6,7,8-hexahydro-5-oxoquinolines, which derivatives are further substituted by a carbonyl group in the 3-position and optionally substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group are antihypertensive agents and coronary vessel dilators. The compounds, of which 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and an amidine.

Abstract: 3,5,6-Trichloropicolinic acid is prepared in a process which comprisesA. reacting by contacting tetrachloropicolinic acid, hydrazine and an alkali reaction medium in water;B. reacting by contacting the thus formed 3,5,6-trichloro-4-hydrazinopicolinic acid intermediate with an alkali metal hydroxide and an alkaline hypochlorite solution; andC. acidifying the reaction mixture with a mineral acid and recovering the desired 3,5,6-trichloropicolinic acid product.